Equities

Pulse Biosciences Inc

Pulse Biosciences Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)16.12
  • Today's Change-0.02 / -0.12%
  • Shares traded80.58k
  • 1 Year change+143.87%
  • Beta1.7247
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is engaged in the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. The Company’s Nano-pulse Stimulation (NPS) technology is an energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. The Company has designed a variety of applicators, or end-effectors, to explore the potential use of the CellFX platform to treat disorders in other medical specialties, such as cardiology, gastroenterology, gynecology, and ear, nose, and throat.

  • Revenue in USD (TTM)0.00
  • Net income in USD-46.13m
  • Incorporated2018
  • Employees56.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Butterfly Network Inc76.22m-98.51m700.97m225.00--3.85--9.20-0.4708-0.47080.36270.85370.25430.64164.45338,755.60-32.87---38.53--29.60---129.25--2.95--0.00---10.21--20.76------
Orthofix Medical Inc784.25m-119.03m713.84m1.63k--1.36--0.9102-3.14-3.1420.7213.760.88441.176.56479,956.60-13.42-8.88-16.31-10.9668.0572.37-15.18-9.281.11-3.120.2069--62.0610.51-666.60--30.01--
Figs Inc548.65m10.84m798.70m354.0079.821.9848.231.460.0590.0593.082.381.111.3365.261,549,845.002.20--2.64--67.67--1.97--3.28--0.00--7.87--6.85------
Embecta Corp1.12bn69.70m807.83m2.20k11.60--7.460.7221.211.2119.36-13.240.88822.1111.60508,590.905.53--7.91--66.42--6.23--1.612.061.88---0.7703---68.52------
Castle Biosciences Inc311.88m6.08m808.85m610.00144.461.8341.422.590.19990.199911.0715.770.65629.157.15511,275.401.28-9.431.40-10.1781.9080.581.95-28.467.64--0.0228--60.3857.3514.41--117.94--
Avanos Medical Inc681.50m21.70m828.15m3.77k38.510.673412.251.220.46790.338514.7026.760.40311.905.16180,721.301.28-0.65271.45-0.733855.5154.453.18-1.601.469.840.1164---1.580.6357-146.05---18.37--
Cytek Biosciences Inc201.21m-10.16m832.12m645.00--2.17--4.14-0.0782-0.07821.522.970.39821.603.72297,647.90-2.01---2.29--54.92---5.05--5.47--0.0083--17.67---571.58------
Paragon 28 Inc245.00m-63.08m870.95m430.00--6.25--3.55-0.7599-0.75992.951.670.8230.63627.06569,755.80-21.19---25.76--75.22---25.75--1.60-4.200.4424--19.30--28.94------
CeriBell Inc-100.00bn-100.00bn898.43m----------------0.336------------------------2.14--0.6304--74.47--20.72------
Bioventus Inc555.06m-39.48m934.09m1.03k--6.28--1.68-0.6172-0.61728.681.830.70231.954.73572,227.80-6.47-5.52-9.13-7.2767.0068.25-9.22-10.940.98661.130.6725--0.04459.936.91--23.51--
Owens & Minor, Inc.10.66bn-48.79m943.04m13.70k--1.084.260.0885-0.6346-0.6346139.2711.352.097.2615.86778,172.30-0.95611.32-1.492.0720.7216.48-0.45760.56140.45192.030.68310.7983.801.87-284.47--25.91--
Pulse Biosciences Inc0.00-46.13m991.65m56.00--12.53-----0.8069-0.80690.001.290.00----0.00-58.03-93.21-62.84-104.99-------12,332.25----0.00---100.00--27.85---15.20--
BioLife Solutions Inc118.41m-26.44m1.17bn409.00--3.61--9.89-0.5826-1.012.597.040.29871.695.58289,513.40-6.67-13.76-7.37-15.0446.1536.76-22.33-42.991.78-4.030.0614---11.4348.6552.49--86.35--
Artivion Inc384.90m-846.00k1.18bn1.50k--3.8551.373.05-0.0235-0.02359.257.270.48791.685.50256,599.30-0.1079-2.20-0.1242-2.3664.5365.51-0.2211-5.341.331.100.51--12.826.14-60.09--5.13--
Establishment Labs Holdings Inc153.07m-70.61m1.19bn933.00--36.43--7.78-2.58-2.585.571.170.55340.79162.51168,580.40-25.53-33.22-31.21-41.1265.0864.73-46.13-43.192.29-4.510.856--2.1321.96-4.38--69.16--
Data as of Nov 21 2024. Currency figures normalised to Pulse Biosciences Inc's reporting currency: US Dollar USD

Institutional shareholders

7.57%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 30 Sep 20241.21m1.98%
The Vanguard Group, Inc.as of 30 Sep 2024939.03k1.53%
Bank of America, NA (Private Banking)as of 30 Sep 2024782.58k1.28%
SSgA Funds Management, Inc.as of 30 Sep 2024461.33k0.75%
Geode Capital Management LLCas of 30 Sep 2024457.17k0.75%
Griffin Asset Management, Inc.as of 30 Sep 2024257.45k0.42%
Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2024210.20k0.34%
Charles Schwab Investment Management, Inc.as of 30 Sep 2024148.11k0.24%
Teachers Advisors LLCas of 30 Sep 2024102.85k0.17%
Westside Investment Management LLCas of 30 Jun 202463.60k0.10%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.